Iambic Therapeutics

aid: iambic-tx
name: Iambic Therapeutics
description: 'Iambic Therapeutics is a San Diego, California AI-driven drug discovery company founded in 2019 by Thomas Miller
  (CEO) and Fred Manby (CTO) that designs small-molecule therapeutics for oncology and other indications. Iambic builds proprietary
  AI models for drug discovery, including Enchant, a multimodal transformer that predicts clinical properties (pharmacokinetics,
  cellular and biochemical activity) of candidate molecules from early discovery data, and NeuralPLexer (now NeuralPLexer3),
  a flow-based generative model for protein-ligand complex structure prediction used to identify cryptic pockets and guide
  structure-based design. Both lines of work have been published at venues including NeurIPS 2025. The company''s internal
  pipeline is oncology-led: IAM1363, a brain-penetrant selective HER2 / HER2-mutant inhibitor, completed Phase 1/1b dose escalation
  in 2025 and is in dose optimization with clinical activity reported at ESMO 2025; IAM-K1 (KIF18A) and IAM-C1 (CDK2/4) are
  preclinical, alongside undisclosed neurology, gastrointestinal, and inflammation discovery programs. In February 2026 Iambic
  announced a discovery and technology collaboration with Takeda worth up to ~$1.7B plus royalties, following a $100M+ private
  financing in November 2025 and total disclosed funding of approximately $334M. The company has been named to the CNBC Disruptor
  50 list in 2025 and 2026 and has signaled intent to access public markets, including via a SPAC. Iambic''s public GitHub
  footprint is limited to np-bench, a BSD-3 benchmark library for 3D biomolecular structure prediction; the underlying NeuralPLexer
  and Enchant models are proprietary and there is no public developer API, SDK, or commercial platform offering.'
type: Index
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
position: Provider
access: 3rd-Party
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/iambic-tx.png
tags:
- AI Drug Discovery
- Drug Discovery
- Therapeutics
- Oncology
- Small Molecules
- HER2
- KIF18A
- CDK2 CDK4
- Multimodal Transformers
- Structure Prediction
- Protein Ligand
- Enchant
- NeuralPLexer
- Biotech
- San Diego
url: https://raw.githubusercontent.com/api-evangelist/iambic-tx/refs/heads/main/apis.yml
created: '2026-05-24'
modified: '2026-05-24'
specificationVersion: '0.20'
apis: []
common:
- type: DomainSecurity
  url: security/iambic-tx-domain-security.yml
- type: Website
  url: https://www.iambic.ai
- type: Platform
  url: https://www.iambic.ai/platform
- type: Pipeline
  url: https://www.iambic.ai/pipeline
- type: Partners
  url: https://www.iambic.ai/partners
- type: About
  url: https://www.iambic.ai/about
- type: News
  url: https://www.iambic.ai/news
- type: Careers
  url: https://www.iambic.ai/careers
- type: Contact
  url: https://www.iambic.ai/contact
- type: Enchant
  url: https://www.iambic.ai/post/enchant-announcement
- type: EnchantV2
  url: https://www.iambic.ai/post/iambic-announces-enchant-v2-its-next-generation-ai-model-for-predicting-the-clinical-viability-of-drug-discovery-programs
- type: NeuralPLexer
  url: https://www.iambic.ai/post/neuralplexer
- type: TakedaCollaboration
  url: https://www.iambic.ai/post/iambic-announces-collaboration-with-takeda
- type: IAM1363ESMO
  url: https://www.iambic.ai/post/esmo-iam1363
- type: IAM1363DoseEscalation
  url: https://www.iambic.ai/post/dose-escalation
- type: GitHub
  url: https://github.com/iambic-therapeutics
- type: NPBench
  url: https://github.com/iambic-therapeutics/np-bench
- type: LinkedIn
  url: https://www.linkedin.com/company/iambic-therapeutics
- url: https://www.iambic.ai/news
  type: Blog
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com